This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/027417-2022">https://www.find-tender.service.gov.uk/Notice/027417-2022</a>

#### Contract

# (NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.

Newcastle University
Durham University
Northumbria University Newcastle Newcastle
University of Sunderland
Teesside University
University of Bath on behalf of the SETsquared

F03: Contract award notice

Notice identifier: 2022/S 000-027417

Procurement identifier (OCID): ocds-h6vhtk-03719a

Published 30 September 2022, 9:41am

# **Section I: Contracting authority**

# I.1) Name and addresses

**Newcastle University** 

Newcastle University, Procurement Services, Kingsgate

Newcastle

NE1 7RU

#### Contact

Mrs Natalie Morton

### **Email**

## natalie.morton@ncl.ac.uk

# **Telephone**

+44 1912086396

## Country

**United Kingdom** 

## Region code

UKC - North East (England)

## Internet address(es)

Main address

https://www.ncl.ac.uk

Buyer's address

https://www.ncl.ac.uk

# I.1) Name and addresses

**Durham University** 

The Palatine Centre, Stockton Road

### **Email**

Edwin.e.milligan@durham.ac.uk

# Country

**United Kingdom** 

# Region code

UKC - North East (England)

## Internet address(es)

Main address

## https://www.durham.ac.uk

# I.1) Name and addresses

Northumbria University Newcastle Newcastle

Newcastle upon Tyne

### **Email**

Hugh.Rhodes@northumbria.ac.uk

## Country

**United Kingdom** 

## Region code

UKC - North East (England)

## Internet address(es)

Main address

https://northumbria.ac.uk

# I.1) Name and addresses

University of Sunderland

Sunderland

### **Email**

Cheryl.Holmstrom@sunderland.ac.uk

## Country

**United Kingdom** 

## Region code

UKC - North East (England)

## Internet address(es)

Main address

https://Sunderland.ac.uk

# I.1) Name and addresses

Teesside University

Middlesbrough, Tees Valley

### **Email**

David.Pratt@tees.ac.uk

## Country

**United Kingdom** 

## Region code

UKC - North East (England)

## Internet address(es)

Main address

https://www.tees.ac.uk/

# I.1) Name and addresses

University of Bath on behalf of the SETsquared

Claverton Down, Bath

#### **Email**

pb487@bath.ac.uk

## Country

**United Kingdom** 

## Region code

UK - United Kingdom

## Internet address(es)

Main address

https://www.bath.ac.uk/

# I.2) Information about joint procurement

The contract involves joint procurement

The contract is awarded by a central purchasing body

# I.4) Type of the contracting authority

Body governed by public law

# I.5) Main activity

Education

# **Section II: Object**

# II.1) Scope of the procurement

### II.1.1) Title

(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.

Reference number

DN621813

### II.1.2) Main CPV code

• 79400000 - Business and management consultancy and related services

## II.1.3) Type of contract

Services

### II.1.4) Short description

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US\$92Bn in 2019 and is expected to reach US\$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US\$35.5Bn Million in 2018 and is projected to reach US\$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

The initial brief of the executive will be to:

Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;

Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board

Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;

- b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO.
- c. Provide to the University of Bath all matters necessary for Research England reporting requirements.

Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding

Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

## II.1.6) Information about lots

This contract is divided into lots: No

### II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £30,000

## II.2) Description

### II.2.3) Place of performance

**NUTS** codes

• UKC - North East (England)

### II.2.4) Description of the procurement

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US\$92Bn in 2019 and is expected to reach US\$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US\$35.5Bn Million in 2018 and is projected to reach US\$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

The initial brief of the executive will be to:

Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;

Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board

Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;

- b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO.
- c. Provide to the University of Bath all matters necessary for Research England reporting requirements.

Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure

seed finance, draft and submit Innovate UK proposal for preclinical funding

Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

### II.2.5) Award criteria

Quality criterion - Name: Ability to meet the required job description / Weighting: Pass/Fail

Quality criterion - Name: Quality: Ability to meet the Job Description / Weighting: Pass/Fail and 60%

Quality criterion - Name: Equity / Weighting: Pass/Fail

Price - Weighting: 40

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

Identification of the project

Northern Accelerator programme involving funding from both the European Regional Development Funding (ERDF) and Research England

# Section IV. Procedure

# **IV.1) Description**

### IV.1.1) Type of procedure

Restricted procedure

### IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the setting up of a dynamic purchasing system

## IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

## IV.2) Administrative information

### IV.2.1) Previous publication concerning this procedure

Notice number: 2022/S 186-528050

# Section V. Award of contract

### **Contract No**

(NU/1433-37)

A contract/lot is awarded: Yes

### V.2) Award of contract

### V.2.1) Date of conclusion of the contract

21 September 2022

### V.2.2) Information about tenders

Number of tenders received: 3

Number of tenders received from SMEs: 3

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 3

Number of tenders received by electronic means: 3

The contract has been awarded to a group of economic operators: No

## V.2.3) Name and address of the contractor

Cambridge Drug Discovery

35 Tunwells Lane, Great Shelford,

Cambridgeshire

**CB22 5LJ** 

Country

**United Kingdom** 

**NUTS** code

• UKC - North East (England)

The contractor is an SME

Yes

## V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £30,000

# **Section VI. Complementary information**

## VI.4) Procedures for review

VI.4.1) Review body

**Newcastle University** 

Tyne and Wear

NE<sub>1</sub> 7RU

Country

**United Kingdom** 

## VI.4.2) Body responsible for mediation procedures

**Newcastle University** 

Tyne and Wear

Country

**United Kingdom** 

### VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

The University will incorporate a standstill period at the point information on the award of the

contract is communicated to tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into.

The Public Contracts Regulations 2015 (SI 2015 No 102) provide for aggrieved parties who

have been harmed or are at risk of harm by a breach of the rules to take action in the High

Court (England, Wales and Northern Ireland) within 30 days of knowledge or constructive knowledge of breach.

# VI.4.4) Service from which information about the review procedure may be obtained

Newcastle University

Tyne and Wear

Country

United Kingdom